Bayesian Graphical Network Analyses Reveal Complex Biological Interactions Specific to Alzheimer's Disease

Abstract

With different approaches to finding prognostic or diagnostic biomarkers for Alzheimer’s disease (AD), many studies pursue only brief lists of biomarkers or disease specific pathways, potentially dismissing information from groups of correlated biomarkers. Using a novel Bayesian graphical network method, with data from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, the aim of this study was to assess the biological connectivity between AD associated blood-based proteins. Briefly, three groups of protein markers (18, 37, and 48 proteins, respectively) were assessed for the posterior probability of biological connection both within and between clinical classifications. Clinical classification was defined in four groups: high performance healthy controls (hpHC), healthy controls (HC), participants with mild cognitive impairment (MCI), and participants with AD. Using the smaller group of proteins, posterior probabilities of network similarity between clinical classifications were very high, indicating no difference in biological connections between groups. Increasing the number of proteins increased the capacity to separate both hpHC and HC apart from the AD group (0 for complete separation, 1 for complete similarity), with posterior probabilities shifting from 0.89 for the 18 protein group, through to 0.54 for the 37 protein group, and finally 0.28 for the 48 protein group. Using this approach, we identified beta-2 microglobulin (β2M) as a potential master regulator of multiple proteins across all classifications, demonstrating that this approach can be used across many data sets to identify novel insights into diseases like AD.

Lactonase Activity and Lipoprotein‐Phospholipase A2 as Possible Novel Serum Biomarkers for the Differential Diagnosis of Autism Spectrum Disorders and Rett Syndrome: Results from a Pilot Study

“…One of the key concept in the definition of an ideal biomarker is that it should be “noninvasive, easily translatable to routine clinical testing, or eventually microfluidic high-throughput population screening and expedient serial monitoring” [ 34 ]. Factors that determine the clinical usefulness of a biomarker include the ease and cost of assessment, its performance characteristics (e.g., sensitivity, specificity, etc.…”

Testing a Combination of Markers of Systemic Redox Status as a Possible Tool for the Diagnosis of Late Onset Alzheimer’s Disease

“…Although showing high analytical performance, CSF biomarkers have not yet achieved the widespread approval and availability necessary in clinical practice. One of the central concept in the definition of an ideal biomarker is that it should be “noninvasive, easily translatable to routine clinical testing or eventually high-throughput population screening, and expedient serial monitoring” [ 5 ]. Blood (serum/plasma) candidate biomarkers, especially when the detection methods are nonexpensive and easy to perform, potentially fit this definition.…”

Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's disease

“…For instance, such models could link Aβ effects on synaptic plasticity ( Anastasio, 2014 ), and the search for potential combination of drugs to reduce microglial inflammation ( Anastasio, 2015 ). More abstract probabilistic graphical (Bayesian) network models were also applied to understand key protein/drug interactions at the systems level ( Rembach et al, 2015 ).…”